A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .
Moclobemide versus fluoxetine for a major depressive episode
The efficacy and tolerability of moclobemide ( 300 or 600 mg daily ) and fluoxetine ( 20 or 40 mg daily ) were compared in a 6-week , double-blind study of 25 in patients and 24 out patients who had major depressive episodes without psychotic features ( DSM-III-R ) . Although the clinical results of this study suggest better efficacy with moclobemide and better tolerability with fluoxetine , a statistically significant difference between treatment groups was noted only with respect to Clinical Global Impressions recorded after 10 days of therapy ; these were significantly better in the moclobemide group . A daily dosage of 300 mg of moclobemide and 20 mg of fluoxetine would thus appear to be comparable both in antidepressant efficacy and tolerability
A metaregression analysis indicated that , after adjusting for possible confounders , studies where fluoxetine was the experimental agent were positively associated with treatment effect , indicating a significant advantage for fluoxetine .
The evidence that the outcome of fluoxetine trials varied according to whether this drug was used as a new compound or a reference one suggests the presence of bias
The present study investigated whether the outcome of r and omized clinical trials study ing fluoxetine favored fluoxetine , where this was the experimental agent , and favored comparator antidepressants in trials where fluoxetine was the reference agent .